Janux Therapeutics, Inc.
- JANX
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- T Cell Engager Platform
$16.74
Today +1.39%Quote Oct 19, 2026, 08:00 PM UTC
+0.90%over the last month
Max drawdown −10.8%From 1-month high −9.5%3 months +3.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Janux Therapeutics
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
113
Founded
2017
Market value
$1.02B
Quote Oct 19
Floor
$15.61
6.7% below price
Resistance
$17.18
2.6% above price
Price vs analyst targets
16 analysts
Lowest target
$14.00Highest target
$55.00
$14.00Highest target
$55.00
- Price $16.74
- Average target $30.14
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 80% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about JANXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free